| Pulmonary arterial hypertension
Letairis vs Veletri
Side-by-side clinical, coverage, and cost comparison for pulmonary arterial hypertension.Deep comparison between: Letairis vs Veletri with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsVeletri has a higher rate of injection site reactions vs Letairis based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Veletri but not Letairis, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Letairis
Veletri
At A Glance
Oral
Daily
Endothelin receptor antagonist
IV infusion
Continuous infusion
Prostacyclin
Indications
- Pulmonary arterial hypertension
- Pulmonary arterial hypertension
Dosing
Pulmonary arterial hypertension Initiate at 5 mg once daily, with or without tadalafil 20 mg once daily; titrate at 4-week intervals as needed and tolerated to Letairis 10 mg or tadalafil 40 mg; do not split, crush, or chew tablets.
Pulmonary arterial hypertension Initiate continuous IV infusion at 2 ng/kg/min via central venous catheter; increase in increments of 2 ng/kg/min every 15 minutes or longer until tolerance limit established or further increases are not clinically warranted; adjust maintenance dose by 1- to 2-ng/kg/min increments at intervals of at least 15 minutes based on symptom persistence or adverse events.
Contraindications
- Pregnancy (Letairis may cause fetal harm when administered to a pregnant female)
- Idiopathic Pulmonary Fibrosis, including IPF patients with pulmonary hypertension (WHO Group 3)
- Chronic use in patients with congestive heart failure due to severe left ventricular systolic dysfunction
- Pulmonary edema developing during dose initiation (associated with pulmonary veno-occlusive disease)
- Known hypersensitivity to epoprostenol or structurally related compounds
Adverse Reactions
Most common (>3% placebo-adjusted) Peripheral edema, nasal congestion, sinusitis, flushing
Postmarketing Anemia requiring transfusion, heart failure (associated with fluid retention), symptomatic hypotension, hypersensitivity (angioedema, rash), liver aminotransferase elevations (ALT, AST)
Most common (dose initiation and escalation) Flushing, headache, nausea, vomiting, hypotension, anxiety, chest pain, dizziness, bradycardia, abdominal pain, musculoskeletal pain, dyspnea, tachycardia
Most common (chronic dosing) Headache, jaw pain, flushing, diarrhea, nausea, vomiting, flu-like symptoms, anxiety
Postmarketing Anemia, hypersplenism, pancytopenia, splenomegaly, high output cardiac failure, hyperthyroidism
Pharmacology
Ambrisentan is a high-affinity, selective ETA receptor antagonist that blocks the vasoconstriction and cell proliferation mediated by endothelin-1 (ET-1) in pulmonary vasculature, where ET-1 concentrations and mRNA are markedly elevated in PAH patients.
Epoprostenol is a naturally occurring prostacyclin (metabolite of arachidonic acid) that produces direct vasodilation of pulmonary and systemic arterial vascular beds, reducing right- and left-ventricular afterload and increasing cardiac output, and inhibits platelet aggregation.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Letairis
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (11/12)
Veletri
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Letairis
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (0/8) · Qty limit (8/8)
Veletri
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Letairis
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Veletri
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$5/momo
Letairis Co-Pay Coupon ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAssistance Fund: MPS II- Hunter Syndrome
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
LetairisView full Letairis profile
VeletriView full Veletri profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.